Loading...
Schizophrenia: synthetic strategies and recent advances in drug design
Azmanova, Maria Pitto-Barry, Anaïs Barry, Nicolas P.E.
Azmanova, Maria
Pitto-Barry, Anaïs
Barry, Nicolas P.E.
Publication Date
2018
End of Embargo
Supervisor
Keywords
Rights
(c) 2018 Royal Society of Chemistry. Full-text reproduced in accordance with the publisher's self-archiving policy.
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
2018-03-09
Institution
Department
Awarded
Embargo end date
Collections
Abstract
Schizophrenia is a complex and unpredictable mental disorder which affects several domains of cognition and behaviour. It is a heterogeneous illness characterised by positive, negative, and cognitive symptoms, often accompanied by signs of depression. In this tutorial review, we discuss recent progress in understanding the target sites and mechanisms of action of second-generation antipsychotic drugs. Progress in identifying and defining target sites has been accelerated recently by advances in neuroscience, and newly developed agents that regulate signalling by the main excitatory neurotransmitters in the brain are surveyed. Examples of novel molecules for the treatment of schizophrenia in preclinical and clinical development and their industrial sponsors are highlighted.
Version
Accepted manuscript
Citation
Azmanova M, Pitto-Barry A and Barry NPE (2018) Schizophrenia: synthetic strategies and recent advances in drug design. MedChemComm. 9(5): 759-782.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article